A new stem cell method for culturing hairfollicles is being developed as an alternative to Minoxidil, finasteride, and RU58841. There are concerns about its cost and accessibility despite plans for commercialization.
Hair loss involves more than just DHT, with genetic factors like TRPS affecting hairfollicles. Treatments such as Amplifica's AMP-601 and AMP-303 target stem cells for potential hair growth solutions.
A permanent hair loss solution could involve reprogramming hairfollicles to resist DHT using mRNA and siRNA. However, high costs, safety concerns, and the pharmaceutical industry's preference for ongoing treatments over one-time cures are major obstacles, with finasteride and minoxidil remaining standard treatments.
The conversation is about using Verteporfin with microneedling as a potential hair loss treatment that may regenerate hairfollicles with minimal scarring. There are concerns about the optimal dosage and the DHT sensitivity of the new follicles.
A user is experiencing worsening hair loss despite using dutasteride, oral minoxidil, ketoconazole, and dermarolling. They are advised to reduce dermarolling frequency and depth to avoid damaging hairfollicles.